Insight
Drawing on our experience working in pharma business development as well as venture capital investment firms, we provide a broad industry perspective to help your messages resonate with your key target audiences.
Strategy
We’re creative problem solvers and we’ll help you develop a tailored communications plan and advise on the best channels to raise your visibility with your target audiences internationally.
Impact
With our long track record of achieving successful results, we’ll make sure our communications programme supports your corporate objectives and delivers a strong return on investment.
Blogs
Lisbon: Charting the New Course for European Life Sciences
Top Tips to Capture the Attention of Investors & Partners at Life Sciences Events
“Scius comes from the Latin word meaning insight, skilled or well informed.”
Case Studies
Advent Life Sciences
Showcasing the significance of two new funds
Amphista Therapeutics
Announcing the company’s Series A financing, leading to raised awareness with potential partners, investors and employees.
Amphista Therapeutics: Series B Financing
Announcing the company's Series B financing, which will be used to accelerate the growing pipeline of potent and selective bifunctional molecules and to extend its proprietary TPD platform.
Anocca
Announcing the company's strategic collaboration with Shinobi Therapeutics to to develop allogeneic TCR-T cell therapies in oncology
BC Platforms
Positioning the company as a thought leader in precision medicine raising awareness with customers and investors.
Epitopea Strategic Cancer Collaboration with MSD(Merck)
Announcing the company's strategic cancer collaboration with major global pharma company, positioning client as a pioneer in developing off-the-shelf immunotherapies.
ExeVir Bio EIB funding case study
Announcing the company's 25 million Euro financing from EIB to advance ExeVir’s COVID19 therapeutic
Igyxos: Raising the profile of a novel infertility treatment
Positioning Igyxos as a thought leader in monoclonal-based fertility innovation and elevating its profile ahead of clinical and investor milestones.
IRBM
Positioning the Company as a leading CDMO and highlighting their group Advaxia Biologics.
LEX Diagnostics | FDA 510(k) Clearance and CLIA Waiver Approval for LEX VELO System
Supporting LEX Diagnostics’ FDA submissions and takeover bid, contributing to its $100m acquisition.
Medicxi
To launch Index’s new spin-out life sciences fund and publicise its first closing.
Microbiotica : First patient dosed announcements
Announcing the first patient dosed (FPD) in two Phase 1b trials for MB310 (ulcerative colitis) and MB097 (advanced melanoma), marking significant progress for Microbiotica in its transition to a clinical-stage company.
MitoRx Case Study: Promoting a published paper
Promoting R&D findings on small molecule mitochondrial modulators
MONCYTE Health Secures €1M Seed Funding to Advance Personalized Cardiovascular Treatment
Strategic support to amplify MONCYTE Health’s €1M seed round and boost visibility among investors and industry stakeholders.
Pneumagen
Raising visibility of its technology platform for the treatment for COVID-19 and supporting a new website and fundraising announcement.
Positioning Concept Life Sciences as a partner of choice from concept to clinic
Positioning a leading CRO as a partner of choice through strategic messaging, media outreach and high-impact trade coverage.
TILT Biotherapeutics
Showcasing Phase 1 clinical trial data for TILT-123 combination therapy for platinum-resistant or refractory ovarian cancer, presented at AACR and ASCO.
Vaccitech
Support with corporate and investor materials and media relations supporting the partnership of its ChAdOx platform with AstraZeneca for a COVID-19 vaccine.
Vaccitech IPO
Coordinated a communications plan with key stakeholders to maximise visibility of Vaccitech's Series B financing and NASDAQ IPO listing
VaxEquity Strategic Collaboration with AstraZeneca
Announcing the company's strategic collaboration with AstraZeneca to Commercialise Self-Amplifying RNA platform
Advent Life Sciences
Showcasing the significance of two new funds
Amphista Therapeutics
Announcing the company’s Series A financing, leading to raised awareness with potential partners, investors and employees.
Amphista Therapeutics: Series B Financing
Announcing the company's Series B financing, which will be used to accelerate the growing pipeline of potent and selective bifunctional molecules and to extend its proprietary TPD platform.
Anocca
Announcing the company's strategic collaboration with Shinobi Therapeutics to to develop allogeneic TCR-T cell therapies in oncology
BC Platforms
Positioning the company as a thought leader in precision medicine raising awareness with customers and investors.
Epitopea Strategic Cancer Collaboration with MSD(Merck)
Announcing the company's strategic cancer collaboration with major global pharma company, positioning client as a pioneer in developing off-the-shelf immunotherapies.
ExeVir Bio EIB funding case study
Announcing the company's 25 million Euro financing from EIB to advance ExeVir’s COVID19 therapeutic
Igyxos: Raising the profile of a novel infertility treatment
Positioning Igyxos as a thought leader in monoclonal-based fertility innovation and elevating its profile ahead of clinical and investor milestones.
IRBM
Positioning the Company as a leading CDMO and highlighting their group Advaxia Biologics.
LEX Diagnostics | FDA 510(k) Clearance and CLIA Waiver Approval for LEX VELO System
Supporting LEX Diagnostics’ FDA submissions and takeover bid, contributing to its $100m acquisition.
Medicxi
To launch Index’s new spin-out life sciences fund and publicise its first closing.
Microbiotica : First patient dosed announcements
Announcing the first patient dosed (FPD) in two Phase 1b trials for MB310 (ulcerative colitis) and MB097 (advanced melanoma), marking significant progress for Microbiotica in its transition to a clinical-stage company.
MitoRx Case Study: Promoting a published paper
Promoting R&D findings on small molecule mitochondrial modulators
MONCYTE Health Secures €1M Seed Funding to Advance Personalized Cardiovascular Treatment
Strategic support to amplify MONCYTE Health’s €1M seed round and boost visibility among investors and industry stakeholders.
Pneumagen
Raising visibility of its technology platform for the treatment for COVID-19 and supporting a new website and fundraising announcement.
Positioning Concept Life Sciences as a partner of choice from concept to clinic
Positioning a leading CRO as a partner of choice through strategic messaging, media outreach and high-impact trade coverage.
TILT Biotherapeutics
Showcasing Phase 1 clinical trial data for TILT-123 combination therapy for platinum-resistant or refractory ovarian cancer, presented at AACR and ASCO.
Vaccitech
Support with corporate and investor materials and media relations supporting the partnership of its ChAdOx platform with AstraZeneca for a COVID-19 vaccine.
Vaccitech IPO
Coordinated a communications plan with key stakeholders to maximise visibility of Vaccitech's Series B financing and NASDAQ IPO listing
VaxEquity Strategic Collaboration with AstraZeneca
Announcing the company's strategic collaboration with AstraZeneca to Commercialise Self-Amplifying RNA platform
Contact
If you would like to learn more about how we can help you, please contact us: info@sciuscommunications.com
Copyright 2020 © Scius Communications | Privacy policy
Website by FisherPaul
